Finance

Perceptive launches $210M early-stage fund tied to Garabedian’s accelerator Xontogeny

Two and a half years after Perceptive Advisors’ Chris Garabedian launched Xontogeny to foster biotech start-ups’ growth, the firm has created a $210 million fund that will invest in companies the accelerator is nurturing through...

Zentalis debuts with trio of clinical oncology programs, $85M series C

Zentalis emerged from stealth Monday with an untranched and oversubscribed $85 million series C and three internally discovered clinical cancer candidates, with plans to begin pivotal testing by 2021. The C round syndicate includes Matrix...

Jasper debuts with $35M series A, licenses antibody from Amgen to prep patients for transplants

With an antibody in-licensed from Amgen and a $35 million series A led by Abingworth and Qiming Venture Partners, Jasper is aiming to make stem cell transplants safer for patients. Surveyor Capital and Alexandria Venture...

Financing Roundup: Immunomedics, Ardelyx, Millendo, Omeros, Athenex

Since market close on Wednesday, Immunomedics, Ardelyx, Millendo and Omeros raised a total of $450 million in follow-ons, while Athenex raised $60 million via a private placement. Immunomedics Inc. (NASDAQ:IMMU) raised $250 million on Wednesday,...

Black Diamond raises $85M series C, shoots to enter clinic next half

As Black Diamond prepares to bring its first cancer candidate to the clinic and build out its tumor-agnostic pipeline, the company has raised $85 million in a oversubscribed series C led by new investor Boxer...

With $75M from Apple Tree, Limelight seeks to overcome limitations of genetic therapy

With a $75 million series A investment, and Biogen veteran Michael Ehlers joining newly launched Limelight Bio as CEO, Apple Tree Partners believes a multiplatform approach to gene therapy can overcome limitations of the modality...

Follow-on Roundup: Arrowhead, Kodiak, Relmada, Revance

Since market close on Tuesday, Arrowhead, Kodiak, Relmada and Revance raised a total of $718.5 million in follow-ons. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) raised $232 million after it priced an offering of 4 million shares at...

Series B boost for ImCheck's gamma delta T cell therapies

With $53 million in series B funding, ImCheck plans to bring at least one of its T cell-activating antibodies into the clinic and broaden its immuno-oncology pipeline. Pfizer Ventures and two Bpifrance funds, InnoBio 2...

Dec. 2 Financial Quick Takes: Kodiak gains on royalty deal; plus Clover, Aslan, Transcenta, EOC, Hui-Gene and ViGeneron

Kodiak in $225M royalty deal with Baker Bros. Kodiak Sciences Inc. (NASDAQ:KOD) gained $21.45 (72%) to $51.05 on Monday after selling royalty rights on global net sales of retinal vascular disease drug KSI-301 to Baker...

Alphamab Oncology sets sights on $220M IPO as HKSE continues to gain momentum

Alphamab Oncology is aiming to raise about HK$1.7 billion ($221.1 million) in an IPO on the Hong Kong stock exchange next week in an offering that would value the company at HK$8.7 billion if priced...

IFM Therapeutics gets $55.5M to launch incubator and new subsidiaries

IFM Therapeutics is doubling down on its asset-centric subsidiary model, raising $55.5 million to launch an incubator and up to three new subsidiaries focused on developing small molecules targeted at the innate immune system for...

Diagnostics play Genetron raises $75M, looks to NASDAQ for China expansion

Seeking to expand its cancer diagnostics business in China, Genetron proposed a NASDAQ IPO and announced completion of venture financing that together could bring the company up to $175 million. Beijing-based Genetron Holdings Ltd. raised...

DigiTx focuses on data in evolving landscape of digital health investing

As one of the few digital therapeutics-focused investors, DigiTx is parsing opportunities in the rapidly expanding field by homing in on companies that use or generate patient data in innovative ways. DigiTx Partners was launched...

Syncona backs Cambridge oncology spinout Azeria in £32M series B

Syncona is taking a majority stake in University of Cambridge spinout Azeria by leading the company's £32 million ($41.5 million) series B round, with which the start-up hopes to bring its first FOXA1 inhibitor into...

Longwood launches Immunitas with $39M and single-cell genomics platform

With $39M series A, Immunitas is harnessing single-cell analysis to identify new immune targets for cancer. Immunitas Therapeutics emerged from stealth mode on Thursday with a $39 million series A round and a single-cell genomics...